Halozyme Therapeutics Inc (HALO)

Cash ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	US$ in thousands	115,850	154,318	187,864	164,627	118,370	274,227	221,165	96,383	234,195	147,159	90,932	117,835	118,719	491,683	446,966	499,450	147,703	65,741	133,606	104,820
Short-term investments	US$ in thousands	480,224	511,988	341,166	298,824	217,630	209,055	127,110	179,225	128,599	118,425	118,428	668,305	622,203	324,237	308,343	264,856	220,310	280,965	251,840	263,363
Total current liabilities	US$ in thousands	139,100	108,815	133,360	131,639	112,494	115,185	116,393	91,919	130,789	109,384	199,512	111,691	117,147	113,153	114,251	107,421	421,385	26,976	26,073	42,002
Cash ratio		4.29	6.12	3.97	3.52	2.99	4.20	2.99	3.00	2.77	2.43	1.05	7.04	6.32	7.21	6.61	7.12	0.87	12.85	14.78	8.77

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($115,850K + $480,224K) ÷ $139,100K
= 4.29

The cash ratio of Halozyme Therapeutics Inc has fluctuated over the years based on the provided data. The cash ratio measures the company's ability to cover its short-term liabilities with its cash and cash equivalents. A higher cash ratio indicates a stronger ability to meet short-term obligations.

The cash ratio of Halozyme Therapeutics Inc ranged from a high of 14.78 on June 30, 2020, to a low of 0.87 on December 31, 2020. The ratio improved in the following quarters but experienced some volatility throughout the years.

From the data, it can be observed that the cash ratio generally remained above 1, indicating that the company had sufficient cash reserves to cover its short-term liabilities. However, a decreasing trend in the cash ratio from a peak of 7.21 on September 30, 2021, to 2.99 on December 31, 2023, followed by a slight recovery, may suggest that the company faced challenges in managing its liquidity during this period.

Overall, while the fluctuations in the cash ratio reflect the company's changing cash position over time, it is essential for Halozyme Therapeutics Inc to maintain a healthy cash ratio to ensure it can meet its short-term financial obligations effectively.